Kiniksa Pharmaceuticals (NASDAQ: KNSA) surged 18.27% to $31.98 in pre-market trading on July 29, 2025, following strong Q2 results.
Volume was notably elevated as the company reported earnings of $0.23 per share, beating estimates of $0.19, and revenue of $156.8 million, topping forecasts of $145.22 million. Year-over-year, KNSA swung from a $0.06 loss to a $0.23 profit, with revenue up 44.3%.
The company also raised its FY 2025 revenue guidance to $625–$640 million, above previous estimates, driving investor optimism.
